EyePoint Pharmaceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders on June 20, 2024, via live webcast. During the meeting, stockholders approved several key proposals, including amendments to the company's incentive plans. The 2023 Plan Amendment was passed, increasing the authorized shares for issuance under the 2023 Long-Term Incentive Plan by 4 million shares and raising the compensation limit for non-employee directors. The incentive stock option limit was also raised from 3.5 million to 7.5 million shares. Additionally, the Second 2019 Plan Amendment was approved, allowing for an increase of 250,000 shares under the 2019 Employee Stock Purchase Plan. The meeting also saw the election of directors, with all nominated members successfully elected to the Board. Furthermore, the stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The company's named executive officers' compensation was approved on a non-binding advisory basis. The proposals received a majority of votes from the 89.09% of outstanding shares represented at the meeting.

EyePoint Pharmaceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders on June 20, 2024, via live webcast. During the meeting, stockholders approved several key proposals, including amendments to the company's incentive plans. The 2023 Plan Amendment was passed, increasing the authorized shares for issuance under the 2023 Long-Term Incentive Plan by 4 million shares and raising the compensation limit for non-employee directors. The incentive stock option limit was also raised from 3.5 million to 7.5 million shares. Additionally, the Second 2019 Plan Amendment was approved, allowing for an increase of 250,000 shares under the 2019 Employee Stock Purchase Plan. The meeting also saw the election of directors, with all nominated members successfully elected to the Board. Furthermore, the stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The company's named executive officers' compensation was approved on a non-binding advisory basis. The proposals received a majority of votes from the 89.09% of outstanding shares represented at the meeting.